|
Zoldonrasib Clinical Trials
4 actively recruiting trials across 4 locations
▲ +2 trials since August 2026
Pipeline
Phase 3: 3Phase 1/2: 1
Top Sponsors
- Revolution Medicines, Inc.4
Indications
- Cancer4
- Pancreatic Adenosquamous Carcinoma2
- PDAC2
- Pancreatic Adenocarcinoma Metastatic2
- Pancreatic Cancer Metastatic2
Tucson, Arizona1 trial
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
The University of Arizona Cancer Center-North Campus
Phase 3
Los Angeles, California1 trial
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
USC Norris Comprehensive Cancer Center
Phase 1/2
Plantation, Florida1 trial
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
Florida Clinical Trials Group, LLC
Phase 3
Tampa, Florida1 trial
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.